Apogee Therapeutics Insider Ups Holding During Year

Simply Wall StJan 6 19:57

Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock

InvestingDec 16, 2024 19:14

Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy

BenzingaDec 12, 2024 23:43

Apogee Therapeutics Advances Clinical Trials for APG333

TipRanksDec 10, 2024 20:59

Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025

BreakingsDec 10, 2024 20:00

Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

BreakingsDec 10, 2024 20:00